• Corpus ID: 25406216

The role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin.

  title={The role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin.},
  author={Hussein Rastegar and Hamidreza Ahmadi Ashtiani and Soghra Anjarani and Saeed Bokaee and Arash Khaki and Leila Javadi},
  journal={Acta medica Iranica},
  volume={51 9},
Breast cancer is the most commonly diagnosed invasive malignancy and first leading cause of cancer-related deaths in Iranian women. Based on silymarin's unique characteristics, its application in chemotherapy combined with doxorubicin can be effective to enhance the efficacy together with a reduced toxicity on normal tissues. The present study focus on evaluate the efficacy of silymarin in combination with doxorubicin, on viability and apoptosis of estrogen-dependent breast carcinoma cell line… 

Tables from this paper

Triple Effect of Doxorubicin, 5-Fluorouracil, Propranolol on Cell Survival on MCF-7 Breast Cancer Cell Line

It is found that the use of doxorubicin, 5-fluorouracil, and propranolol in combination is much effective than their single application, and being applied in combination as a novel therapy option is highly possible.

Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity

Silymarin and its derivatives play a double role, namely, limiting the progression of cancer cells through different phases of the cycle and accumulating cancer cells in a phase of the cell cycle—thus making it possible to target a greater number of tumor cells with a specific anticancer agent.

Paeoniflorin inhibits doxorubicin-induced cardiomyocyte apoptosis by downregulating microRNA-1 expression.

The results suggest that the inhibitory effect of PEF on DOX-induced cardiomyocyte apoptosis may be associated with downregulation of miR-1 expression via a reduction in ROS generation.

Milk Thistle: Its Anti-Tumor Potential

Ongoing research has focused on the improvement of milk thistle’s bioavailability and its use as an adjuvant in standardized chemotherapy in the near future.

Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions

This review deals with recent investigations to elucidate the molecular actions of this flavonoid in cancer, and to consider the possibility of repurposing it.

Molecular studies of breast cancer in Iran: A Systematic Review

Results of this review showed that most of the researches in Iran categorize to 4 main subjects, and stronger studies would require the development of more biological banks and execution of multicenter comprehensive projects defined with orientation to main problems of Breast Cancer patients in the country.

Mesoporous silica coated SPIONs containing curcumin and silymarin intended for breast cancer therapy

The prepared formulation may offer a novel theranostic system for breast cancer researches because the NPs indicated proper MRI features and cellular uptake through endocytosis.

Quantitative analysis and comparison of 3D morphology between viable and apoptotic MCF-7 breast cancer cells and characterization of nuclear fragmentation

The results of these studies reveal that the 3D morphological changes in cytoplasm and nuclear membranes in apoptotic cells provide sensitive targets for label-free detection and staging of apoptosis and are highly useful for derivation of optical cell models and simulation of diffraction images.

Antibacterial Activity of Protease Hydrolysates Isolated from Silybum marianum

A preliminary report on the excavation at the Neolithic site of Law Nongthroh (Sohpet Bneng) and a report on archaeological exploration and excavation at Kamla Valley with reference to Parsi Parlo of Lower Subansiri District are published.



Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata.

Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.

Findings suggest a need for in vivo studies with this combination of silibinin and doxorubicin against prostate cancer, which is limited because of high systemic toxicity, and might be relevant for a clinical application in prostate cancer patients.

Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.

Results suggest a possible synergism between silibinin and conventional cytotoxic agents for breast cancer treatment, and warrant further in vivo studies in pre-clinical breast cancer models.

Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins.

  • X. ZiD. FeyesR. Agarwal
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
Results suggest that sily marin may exert a strong anticarcinogenic effect against breast cancer and that this effect possibly involves an induction of Cip1/p21 by silymarin, which inhibits the threshold kinase activities of CDKs and associated cyclins, leading to a G1 arrest in cell cycle progression.

Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.

These findings extend and translate the observations on in vitro anticancer effect of silibinin/silymarin to an in vivo preclinical PCA model, which may form the basis for a Phase I clinical trial in PCA patients.

Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.

The results obtained in this study could be clinically relevant in terms of both MDR reversal in cancer treatment and drug-flavonoid pharmacokinetic interactions.

Proliferation of human breast cancer cells and anti‐cancer action of doxorubicin and vinblastine are independent of PKC‐α

Exposure for 24 h to doxorubicin (DOX) and vinblastine (VIN) caused a concentration‐dependent reduction in proliferation of MCF‐7 cells, but these two anticancer drugs altered cellular morphology and growth pattern in distinct manners are suggested to be independent of PKC‐α.

Oral Silibinin Inhibits Lung Tumor Growth in Athymic Nude Mice and Forms a Novel Chemocombination with Doxorubicin Targeting Nuclear Factor κB–Mediated Inducible Chemoresistance

It is reported that oral silibinin (a flavanone) suppresses human non–small-cell lung carcinoma A549 xenograft growth and enhances the therapeutic response and reduces systemic toxicity of doxorubicin with an enhanced therapeutic efficacy most likely via an inhibition ofDoxorUBicin-induced chemoresistance involving NFκB signaling.

Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis.

The data suggest that silymarin and/or its major active constituent silibinin could be an effective agent for both prevention and intervention of human skin cancer.

Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha.

Results indicate that silymarin exerts novel chemopreventive effects against tumorigenicity by inhibiting endogenous tumor promoter TNF alpha.